

THE REPUBLIC OF CYPRUS

Department of Registrar of Companies and Official Receiver

**ΚΥΠΡΙΑΚΟ ΓΡΑΦΕΙΟ ΔΙΠΛΩΜΑΤΩΝ
ΕΥΡΕΣΙΤΕΧΝΙΑΣ
THE PATENT OFFICE OF CYPRUS**

**ΑΡΙΘΜΟΣ ΔΗΜΟΣΙΕΥΣΗΣ CY1533
PUBLICATION NUMBER**

ΑΡΙΘΜΟΣ ΔΗΜΟΣΙΕΥΣΗΣ
ΓΡΑΦΕΙΟΥ ΔΙΠΛΩΜΑΤΩΝ ΕΥΡΕΣΙΤΕΧΝΙΑΣ
ΗΝΩΜΕΝΟΥ ΒΑΣΙΛΕΙΟΥ
UK PATENT OFFICE
PUBLICATION NUMBER GB2140799

Το έγγραφο που παρουσιάζεται πιο κάτω καταχωρήθηκε στο «Γραφείο Διπλωμάτων Ευρεσιτεχνίας» στην Αγγλία σύμφωνα με το Νόμο Κεφ. 266 πριν την 1^η Απριλίου 1998. Δημοσίευση έγινε μετέπειτα από το Γραφείο Διπλωμάτων Ευρεσιτεχνίας του Ηνωμένου Βασιλείου μόνο στην Αγγλική γλώσσα.

**The document provided hereafter was filed at "The Patent Office"
in England under the law CAP.266 before the 1st of April 1998.
It was published afterwards by the UK patent office only in English.**

(12) UK Patent Application (19) GB (11) 2 140 799 A

(43) Application published 5 Dec 1984

(21) Application No 8409242

(22) Date of filing 10 Apr 1984

(30) Priority data

(31) 484016
581291

(32) 11 Apr 1983
24 Feb 1984

(33) US

(51) INT CL³

C07D 487/14 A61K 31/40 (C07D
487/14 203/00 209/00)

(52) Domestic classification

C2C 1173 1292 1341 1416 1530 1600 213 214 215
220 222 226 22Y 246 247 250 251 252 25Y 28X
30Y 313 31Y 321 322 32Y 332 333 338 339 340
341 342 34Y 351 352 353 360 361 364 366 368
36Y 370 37Y 627 637 70Y 802 80Y AA RA
U1S 1313 C2C

(71) Applicant

Bristol-Myers Company (USA-Delaware),
345 Park Avenue, New York 10154, United States of
America

(56) Documents cited

GB A 2106096

(72) Inventors

Dolatrai Mohanlal Vyas
Terrence William Doyle
Yulin Chiang

(58) Field of search


C2C

(74) Agent and/or Address for Service

Carpmaels & Ransford,
43 Bloomsbury Square, London WC1A 2RA

(54) Pyrroloindole derivatives

(57) The present invention refers mitomycin C derivatives in which the 7-amino group bears an organic substituent incorporating a disulfide group and which are of formula



where R⁹ is an organic group, Alk₂ is an alkylene group and R is hydrogen, alkyl or acyl. The compounds are inhibitors of experimental animal tumors.

GB 2 140 799 A


SPECIFICATION

Pyrroloindole derivatives

- 5 The present invention refers to mitomycin analogs containing a disulfide group (Class 260 Subclass 326.24). These compounds are mitomycin C derivatives in which the 7-amino group bears an organic substituent incorporating a disulfide group. These compounds are inhibitors of experimental animal tumors.


Nomenclature—The systematic Chemical Abstracts name for mitomycin C is:

- 10 [1aR-1α,8β,8α,8bα]-6-amino-8-[[[(aminocarbonyl)-oxy)methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methyl-arizino[2',3',3,4,]pyrrolo[1,2-a] indole-4,7-dione according to which the azirinopyrroloindole ring system is numbered as follows:



Chemical Abstracts

- A trivial system of nomenclature which has found wide use in the mitomycin literature identifies the foregoing ring system including several of the characteristic substituents of the mitomycins as mitosane.



Mitosane

- We have chosen in the present specification to use this system and to refer to the azirino nitrogen atom as N^{1a} and the ring amino nitrogen atom as N⁷. As to the stereochemical configuration of the products of this invention, it is intended when identifying them by the root name "mitosane" or by structural formula to identify the stereochemical configuration thereof as the same as that of mitomycin C.

Description of the Prior Art

- Mitomycin C is an antibiotic which is produced by fermentation and is presently on sale under Food and Drug Administration approval for the therapy of disseminated adenocarcinoma of the stomach or pancreas in proven combinations with other approved chemotherapeutic agents and as palliative treatment when other modalities have failed (Mutamycin® Bristol Laboratories, Syracuse, New York 13201, Physicians' Desk Reference 35th Edition, 1981, pp. 717 and 718). Mitomycin C and its production by fermentation is the subject of U.S. Patent No. 3,660,578 patented May 2, 1972 claiming priority from earlier applications including an application filed in Japan on April 6, 1957.

- The structures of mitomycins A, B, C, and of porfiromycin were first published by J.S. Webb et al, of Lederle Laboratories Division American Cyanamid Company, J. Amer. Chem. Soc. 84, 3185-3187 (1962). One of the chemical transformations used in this structure study to relate mitomycin A and mitomycin C was the conversion of the former, 7-9α-dimethoxymitosane, by reaction with ammonia to the latter, 7-amino-9α-methoxymitosane. Displacement of the 7-methoxy group of mitomycin A has proven to be a reaction of considerable interest in the preparation of antitumor active derivatives of mitomycin C. The following articles and patents each deal with the conversion of mitomycin A to a 7-substituted amino mitomycin C derivative having antitumor activity. The object of this research was to prepare derivatives which were more active, and particularly which were less toxic than mitomycin C:

- Matsui et al. "The Journal of Antibiotics", XXI, 189-198 (1968).

- Kinoshita et al. J. Med. Chem. 14, 103-109 (1971).

Iyengar et al. J. Med. Chem. 24, 975-981 (1981).

Iyengar, Sami, Remers, and Bradner, Abstracts of Papers 183rd Annual Meeting of the American Chemical Society, March 1982, No. MEDI 72.

Iyengar, et al. J. Med. Chem. 1983, 26, 16-20.

- 5 Iyengar, et al. Abstracts of Papers, 185th Annual Meeting of the American Chemical Society, March 1983, No. MEDI 82. 5

The following patents deal with the preparation of 7-substituted aminomitosane derivatives by the reaction of mitomycin A, mitomycin B, or an N^{1a}-substituted derivative thereof with a primary or secondary amine:

- 10 Cosulich et al. U.S. Patent No. 3,332,944 patented July 25, 1967 10
 Matsui et al. U.S. Patent No. 3,420,846 patented January 7, 1969
 Matsui et al. U.S. Patent No. 3,450,705 patented June 17, 1969
 Matsui et al. U.S. Patent No. 3,514,452 patented May 26, 1970
 Nakano et al. U.S. Patent No. 4,231,936 patented November 4, 1980
 15 Remers, U.S. Patent No. 4,268,676 patented May 19, 1981 15
 Remers, Belg. 893,162, patented May 12, 1982.

Mitomycin C derivatives having a substituted amino substituent in the 7-position have also been prepared by directed biosynthesis, that is by supplementing fermentation broths with a series of primary amines, and carrying out the conventional mitomycin fermentation (C. A.

- 20 Claridge et al. Abst. of the Annual Meeting of Amer. Soc. for Microbiology 1982. Abs. 028). 20

Mitomycin C is the principal mitomycin produced by fermentation and is the commercially available form. Current technology for the conversion of mitomycin C to mitomycin A for use in the production of the semisynthetic substituted amino analogs of mitomycin C referred to in the foregoing patents and publications involves hydrolysis of mitomycin C to the corresponding 7-hydroxymitosane, a highly unstable compound, and then methylation of that substance with diazomethane which is a very hazardous substance to handle. One attempt to avoid the use of diazomethane for methylation involves the use of 7-acyloxymitosanes (Kyowa Hakko Kogyo KK Japanese Patent No. J5 6073-085, Farmdoc No. 56227 D/31) for mitomycin C analog synthesis.

- 30 30

Summary of the Invention

The present invention is concerned with a group of mitomycin C analogs having a dithio organic substituent on the amino nitrogen atom in the 7-position. These compounds may be represented by the following formula

- 35 35



wherein R⁹ is an organic group, viz. the structural component of an organic thiol of the formula R⁹SH, and Alk₂ and R have the meanings given below. These compounds are alternatively described by Formulas I and II

- 45 45



- 55 I and 55



II

wherein:

Alk₁ is a straight or branched chain alkylene group having 1 to 6 carbon atoms when R⁷ is joined thereto through a carbon atom thereof, and 2 to 6 carbon atoms when R⁷ is joined thereto through a sulfur, oxygen, or nitrogen atom thereof, and R⁷ and -SS- are in that instance joined to different carbon atoms

Alk₂ is a straight or branched chain alkylene group having 2 to 6 carbon atoms optionally bearing an R⁷ substituent wherein the sulfur and nitrogen atoms connected thereto and any optional R⁷ substituent connected thereto through oxygen sulfur or nitrogen are attached to different carbon atoms of Alk₂,


Alk₁ and Alk₂ may contain a double bond,

R is hydrogen, lower alkyl, lower alkanoyl, benzoyl, or substituted benzoyl wherein said substituent is lower alkyl, lower alkoxy, halo, amino, or nitro,


R⁷ is selected from the group consisting of hydroxy, halo, amino, alkylamino or dialkylamino having 1 to 12 atoms, alkanoylamino, benzoylamino or A-substituted benzoylamino, naphthoylamino or A-substituted naphthoylamino, cycloalkyl or A-substituted cycloalkyl each having 3 to 8 ring members, cycloalkenyl or A-substituted cycloalkenyl each having 5 to 8 ring members, phenyl or A-substituted phenyl, naphthyl or A-substituted naphthyl, a heterocyclic group selected from the group consisting of heteroaromatic and heteroalicyclic groups having from 1 to 2 rings, from 3 to 8 ring members in each ring, and from 1 to 4 hetero atoms selected from oxygen, nitrogen, and sulfur, alkoxy or alkylthio each having 1 to 6 carbon atoms, carboxy, alkoxycarbonyl having 1 to 7 carbon atoms, phenoxycarbonyl or A-substituted phenoxycarbonyl, phenoxy or A-substituted phenoxy, naphthoxy or A-substituted naphthoxy, alkoxycarbonylamino having 2 to 6 carbon atoms, guanidino, ureido (-NHCONH₂), N-alkylureylene (-NHCONHalkyl) having 2 to 7 carbon atoms, N³-haloalkylureylene having 3 to 7 carbon atoms, N³-haloalkyl-N³-nitrosoureylene having 3 to 7 carbon atoms, and dialkylaminocarbonyl having 3 to 13 carbon atoms, wherein said A substituent is selected from the group consisting of one or two lower alkyl, lower alkanoyl, lower alkoxy, halo, amino, hydroxy, or nitro groups, and

R⁸ is selected from the group consisting of alkyl having 1 to 12 carbon atoms, alkenyl or alkynyl each having 3 to 12 carbon atoms, cycloalkyl having 3 to 8 ring members, A-substituted cycloalkyl having 3 to 8 ring members, cycloalkenyl having 5 to 8 ring members, phenyl, A-substituted phenyl, naphthyl, A-substituted naphthyl, a heterocyclic group selected from the group consisting of heteroaromatic and heteroalicyclic groups having from 1 to 2 rings, from 3 to 8 ring members in each ring, and from 1 to 4 hetero atoms selected from oxygen, nitrogen, and sulfur, wherein said A substituent is selected from the group consisting of one or two lower alkyl, lower alkanoyl, lower alkoxy, halo, amino, hydroxy or nitro groups, and R⁸ and the adjacent sulfur atom together constitute S-cysteinyl wherein said S-cysteinyl group may be esterified, salified, or joined within a peptide bond.

The substances of this invention are inhibitors of experimental tumors in animals. They are prepared by reacting an aminodisulfide of Formulas III or IV




III




IV

with a mitosane derivative of Formula V



V

wherein Y is a group readily displacable by reaction with a primary amine to yield an N⁷-substituted mitomycin C derivative. Such mitosane derivatives include mitomycin A and its homologs of Formula V wherein Y is a lower alkoxy group of 1 to 6 carbon atoms. Another is the derivative having Formula V wherein Y is the amidino group of Formula VI.



wherein:

R⁵ is hydrogen (preferred), lower alkyl, phenyl, lower alkylphenyl, lower alkoxyphenyl, halophenyl, aminophenyl, or nitrophenyl, and

R³ and R⁴ are independently lower alkyl, or together with the nitrogen atom to which they are attached constitute pyrrolidine, 2-, or 3-lower alkylpyrrolidine, piperidine, 2-, 3-, or 4-lower alkylpiperidine, 2,6-dilower alkylpiperidine, piperazine, 4-substituted piperazine (wherein said 4-substituent is alkyl, or carbalkoxy each having 1 to 8 carbon atoms, phenyl, methylphenyl, methoxyphenyl, halophenyl, nitrophenyl, or benzyl), azepine 2-, 3-, 4-, or 5-lower alkylazepine, morpholine, thiomorpholine, thiomorpholine-1-oxide, or thiomorpholine-1, 1-dioxide,

10 wherein

each of the aforesaid lower alkyl, lower alkanoyl and lower alkoxy groups contains 1 to 6 carbon atoms.

The later are amidino derivatives of mitomycin C and are described in copending application Serial No. 385,149 filed June 4, 1982.

15

Detailed Description of the Invention

The reaction between the mitosane derivative of Formula V and the aminodisulfide of Formula III or Formula IV takes place in an anhydrous liquid organic reaction medium at a temperature in the range of from about -15°C to +50°C. A temperature in the range of from 0°C to 20°C is preferred. Any anhydrous liquid organic reaction medium may be employed so long as it is stable under the reaction conditions and does not participate in the reaction in a deleterious way. From 1 to 4 molar portions of the aminodisulfide of Formulas III or IV are employed with the mitosane reactant of Formula V. Preferably equimolar amounts of the two reactants are employed. A reaction period of several hours and preferably from about 8 to 50 hours is employed. The product is recovered chromatographically which may suitably involve evaporating of the liquid organic reaction medium and chromatography of the residue.

25


Aminodisulfides of Formula III and Formula IV are known compounds and may be prepared by various methods. For instance, they may be made by reaction of the appropriate thiol R⁷Alk₁SH or R⁸SH with a Bunte salt of the formula

30



or with a sulphenylthiocarbonate of the formula

35



Klayman et al. Journal of Organic Chemistry 29, 3737-3738 (1964) have prepared the following by the Bunte salt method.

40

2-aminoethyl n-butyl disulfide
2-aminoethyl n-hexyl disulfide
2-aminoethyl n-octyl disulfide
2-aminoethyl n-decyl disulfide
2-aminoethyl phenyl disulfide
2-aminoethyl benzyl disulfide

45

Methanol was found to be the preferred reaction solvent for the reaction of the Bunte salt with the thiol. Reaction temperatures of 0° to -10°C were found to be preferred using this solvent. Higher temperatures were necessary with other solvents. The chief drawback of this method is the formation of symmetrical disulfides as a by-product, presumably as a result of disproportionation of the desired mixed disulfide.

50

The mixed disulfide starting materials of Formulas III and Formula IV are preferably prepared via reaction of the appropriate thiol, with a sulphenylthiocarbonate of Formula VIII. This is the method of S. J. Brois et al. Journal of the American Chemical Society 92, 7269-7270 (1970). Typically this preparative procedure involves adding the thiol to a methanol solution of the amino-alkylsulphenylthiocarbonate of Formula VIII and allowing the reaction to proceed at a temperature in the range of from 0° to 25°C. Reaction times vary from virtually instantaneous to several hours depending upon the particular thiol employed. The process of the reaction can be followed by measuring the presence of unreacted thiol in the reaction vessel. If the reaction is sluggish, a catalytic amount of triethylamine may be added as reaction accelerator.

55


The following is an enumeration of representative thiols of the formulas R⁷Alk₁SH or R⁸SH which may be converted via reaction with the Bunte salt VII or sulphenylthiocarbonate VIII to produce intermediates Formulas III and IV which in turn are converted to products of the

60

65

present invention as described. In the case of the amino containing thiols in the following enumeration, it is generally desirable to first convert them to a protected form, preferably the β -(trimethylsilyl)ethoxycarbonylamino derivative, prior to conversion to the intermediates of Formulas III or IV and reaction with the mitosane intermediate of Formula V. The β -(trimethylsilyl)ethoxycarbonylamino group can then be subsequently cleaved by treatment with tetraethylammonium fluoride in acetonitrile (L.A. Carpino et al., J.C.S. Chem. Comm., 358 (1978)) to yield the desired free amino compound of Formula I or II.











- 5 HSCH_3 5
- 10 HSCH_2CH_3 10
 $\text{HSCH}_2\text{CH}_2\text{CH}_3$
 $\text{HSCH}(\text{CH}_3)_2$
 $\text{HS}(\text{CH}_2)_3\text{CH}_3$
- 15 $\text{HS}-\underset{\text{CH}_3}{\text{CH}}-\text{CH}_2\text{CH}_3$ 15
- 20 $\text{HSCH}_2\text{CH}(\text{CH}_3)_2$ 20
- 25 $\text{HS}-\underset{\text{CH}_3}{\overset{\text{CH}_3}{\text{C}}}-\text{CH}_3$ 25
- 30 $\text{HS}-\triangle$ 30
- 35 $\text{HS}-\square$ 35
- 40 $\text{HS}-\text{C}_5\text{H}_9$ 40
- 45 $\text{HS}-\text{C}_6\text{H}_{11}$ 45
- 50 $\text{HS}-\text{C}_6\text{H}_7$ 50
- 55 $\text{HS}-\text{CH}_2-\text{C}_6\text{H}_{11}$ 55
- 60 $\text{HS}-\text{CH}_2-\text{CH}=\text{CH}_2$
 $\text{HS}-\text{CH}_2-\text{CH}=\text{C}(\text{CH}_3)_2$
 $\text{HS}-\text{CH}_2-\text{C}\equiv\text{CH}$
 $\text{HS}-\text{CH}_2-\text{C}\equiv\text{C}-\text{CH}_3$ 60




- $$\text{HS}(\text{CH}_2)_n\overset{\text{O}}{\parallel}\text{CXR} \quad n = 1-3, X = \text{O}, \text{NH}, \text{NR}^1; R, R^1 = \text{H}, \text{CH}_3$$
- 5 $\text{HS}(\text{CH}_2)_n\text{NH}_2 \quad n = 2-4$ 5
- 10 $\text{HS}(\text{CH}_2)_n\text{NHR}^1 \quad n = 2-4, R^1\text{CH}_3, \text{CH}_2\text{CH}_3, \text{CH}_2\text{CH}_2\text{CH}_3, \overset{\text{O}}{\parallel}\text{CCH}_3$ 10
 $\text{HS}(\text{CH}_2)_n\text{NR}^1\text{R}^2 \quad n = 2-4, R^1/R^2 = \text{CH}_3, \text{CH}_2\text{CH}_3$
- 15 $\text{HS}-\overset{\text{CH}_3}{\underset{|}{\text{CH}}}-\text{CH}_2\text{NH}_2$ 15
- 20 $\text{HS}-\overset{\text{CH}_3}{\underset{\text{CH}_3}{| \text{C}}}-\text{CH}_2\text{NH}_2$ 20
- 25 $\text{HS}-\text{CH}_2-\overset{\text{CH}_3}{\underset{|}{\text{CH}}}-\text{NH}_2$ 25
- 30 $\text{HS}-\text{CH}_2-\overset{\text{CH}_3}{\underset{\text{CH}_3}{| \text{C}}}-\text{NH}_2$ 30
- 35 $\text{HS}-\text{CH}_2\text{CH}_2\text{SCH}_3$
 $\text{HS}-\text{CH}_2\text{CH}_2\text{NHC}(\text{CH}_3)_3$ 35
- 40 $\text{HS}-\text{CH}_2-\overset{\text{CH}_3}{\underset{\text{CH}_3}{| \text{C}}}-\text{CH}_2\text{NHR}^1 \quad R^1 = \text{H}, \text{CH}_3, \overset{\text{O}}{\parallel}\text{CCH}_3$ 40
- 45 $\text{HS}-\text{CH}_2\text{CH}_2-\text{NH}-\text{C}_6\text{H}_{11}$ 45
- 50 $\text{HS}-\text{CH}_2\text{CH}_2-\text{N} \begin{array}{l} \text{CH}_2 \\ | \\ (\text{CH}_2)_n \end{array} \quad n = 3-5$ 50
- 55 $\text{CH}_2\text{NR}^1\text{R}^2$
 $\text{HS}-\overset{|}{\text{CH}}-\text{CH}_2\text{NR}^1\text{R}^2 \quad R^1 = \text{H}, \text{CH}_3; \quad R^2 = \text{H}, \text{CH}_3$ 55
- 60 $\text{HS}-\text{CH}_2-\overset{\text{NHR}^1}{\underset{|}{\text{CH}}}-\text{CH}_2\text{NHR}^1 \quad R^1 = \text{H}, \text{CH}_3$ 60

	$\text{HS}-\text{CH}_2-\underset{\text{OH}}{\text{CH}}-\text{CH}_2\text{NH}_2$	
5	$\text{HS}-\text{CH}_2-\underset{\text{CH}_2\text{NH}_2}{\text{CH}}-\text{CH}_2\text{NH}_2$	5
10	$\text{HS}-\text{CH}_2-\underset{\text{CO}_2\text{H}}{\text{CH}}-\text{NH}_2$	10
15	$\text{HS}-\text{CH}_2-\underset{\text{CO}_2\text{H}}{\text{CH}}-\text{CH}_2-\text{NH}_2$	15
20	$\text{HS}-\text{CH}_2-\underset{\text{NH}_2}{\text{CH}}-\text{CH}_2-\text{CO}_2\text{H}$	20
25	$\text{HS}-\text{CH}_2\text{CH}_2-\underset{\text{NH}_2}{\text{CH}}-\text{CH}_2\text{CO}_2\text{H}$	25
30	$\text{HS}(\text{CH}_2)_n-\underset{\text{NHR}^1}{\overset{\text{NR}^2}{\text{C}}}$ $n = 1-3, R^2 = \text{H}, \text{CH}_3, R^1 = \text{H}, \text{CH}_3$	30
35	$\text{HS}-\text{CH}=\text{CH}-\text{NHC}(=\text{O})\text{CH}_3$	35
40	$\text{HS}-\text{CH}_2-\underset{\text{NH}_2}{\text{C}}_3\text{H}_5$ $\text{HS}-\text{CH}_2-\underset{\text{NH}_2}{\text{C}}_3\text{H}_5$	40
45	$\text{HS}-\text{CH}_2-\underset{\text{NH}_2}{\text{C}}_3\text{H}_5$ $\text{HS}-\text{CH}_2-\underset{\text{NH}_2}{\text{C}}_3\text{H}_5$	45
50	$\text{HS}-\text{CH}_2-\underset{\text{NH}_2}{\text{C}}_3\text{H}_5$ $\text{HS}-\text{CH}_2-\underset{\text{NH}_2}{\text{C}}_3\text{H}_5$	50
55	$\text{HS}-\text{CH}_2-\underset{\text{NH}_2}{\text{C}}_4\text{H}_8$ $\text{HS}-\text{CH}_2-\underset{\text{NH}_2}{\text{C}}_4\text{H}_8$	55
60	$\text{HS}-\text{CH}_2-\underset{\text{NH}_2}{\text{C}}_4\text{H}_8$ $\text{HS}-\text{CH}_2-\underset{\text{NH}_2}{\text{C}}_4\text{H}_8$	60
	$\text{HS}-\text{CH}_2\text{CH}_2-\underset{\text{OCH}_3}{\text{N}}-\text{CH}_3$	
	$\text{HS}-\text{CH}_2-\underset{\text{OCH}_3}{\text{CH}}-\text{CH}_2\text{NH}_2$	
	$\text{HS}-\text{CH}_2-\underset{\text{CH}_3}{\text{C}}-\underset{\text{CH}_3}{\text{C}}(\text{NH})-\text{NH}_2$	
	$\text{HS}-\text{CH}_2-\underset{\text{OCH}_3}{\text{CH}}-\underset{\text{NH}}{\text{C}}-\text{NH}_2$	
	$\text{HS}-\text{CH}_2-\text{CH}=\text{CH}-\text{CH}_2\text{NH}_2$	


5		$\text{HS}-\text{CH}_2-\text{C}(\text{CH}_2\text{NH}_2)=\text{CH}_2$	5
10	$\text{HS}-\text{CH}_2-\text{CH}(\text{OH})-\text{CH}_2\text{OH}$	$\text{HS}-\text{CH}_2-\text{CH}(\text{CH}_3)_2\text{CH}_2\text{CH}_2\text{NH}_2$	10
15	5-thio-D-glucose		15
20		$\text{HS}-\text{CH}_2\text{CH}_2\text{NH}-\text{C}_6\text{H}_5$	20
25		$\text{HS}-\text{CH}_2\text{CH}_2\text{NH}-\text{C}_5\text{H}_4\text{N}$	25
30	$\text{HS}-\text{CH}_2-\text{C}(\text{NH}_2)(\text{H})-\text{CH}_2\text{OH}$	$\text{HS}-\text{CH}_2\text{CH}_2\text{NH}-\text{C}_4\text{H}_3\text{NS}$	30
35	$\text{HS}-\text{CH}_2-\text{CH}(\text{CH}_3)-\text{CH}_2\text{OH}$		35
40	$\text{HS}-\text{CH}_2-\text{CH}_2-\text{O}-\text{C}(\text{CH}_3)_2$		40
45			45
50			50
55			55
60			60

5		5
10		10
15		15
20		20
25		25
30		30
35		35
40		40
45		45
50		50
55		55
60		60


$X = N, O$ $Y = H$
 $X = S$ $Y = H, Cl, OCH_2CH_3$



5




10

R = H; CH₃


15

20


20



25




30



X = NH, S


35




40

45


45




50




55




60



5




10




15

20


20




25

 $n = 1, 2$

30




35

 $R^1 = OCH_2CH_3$


40

45


45













50
















55

 $X = O, S, NH$

60

5		X = O, S, NH	5
10		X = O, S, NH	10
15		X = O, S, NH	15
20			20
25		X = O, S, NH	25
30			30
35		R ¹ = H, CH ₃	35
40		R ¹ = H, CH ₃	40
45			45
50		X = O, NH, NCH ₃	50
55		R ¹ = H, CH ₃	55
60		R ¹ = H, CH ₃	60

5		$R^1 = H, CH_3$	5
10		$R^1 = H, CH_3$	10
15		$R^1 = H, CH_3$	15
20			20
25		$R^1 = H, CH_3$	25
30		$n = 1-3, m = 1-3$	30
35		$R^2 = H, CH_3, R^1 = H, CH_3, NH_2$	35
40			40
45		$R^1 = H, CH_3$	45
50		$R^1 = H, CH_3$	50
55			55
60			60



Activity Against P-388 Murine Leukemia

Table I contains the results of laboratory tests with CDF₁ female mice implanted intraperitoneally with a tumor inoculum of 10⁶ ascites cells of P-388 murine leukemia and treated with various doses of either a test compound of Formulas I or II, or with mitomycin C. The compounds were administered by intraperitoneal injection. Groups of six mice were used for each dosage amount and they were treated with a single dose of the compound on the day of inoculation. A group of ten saline treated control mice was included in each series of experiments. The mitomycin C treated groups were included as a positive control. A 30 day protocol was employed with the mean survival time in days being determined for each group of mice and the number of survivors at the end of the 30 day period being noted. The mice were weighed before treatment and again on day six. The change in weight was taken as a measure of drug toxicity. Mice weighing 20 grams each were employed and a loss in weight of up to approximately 2 grams was not considered excessive. The results were determined in terms of % T/C which is the ratio of the mean survival time of the treated group to the mean survival time of the saline treated control group times 100. The saline treated control animals usually died within nine days. The "maximum effect" in the following Table is expressed as % T/C and the dose giving that effect is given. The values in parenthesis are the values obtained with mitomycin C as the positive control in the same experiment. Thus a measure of the relative activity of the present substances to mitomycin C can be estimated. A minimum effect in terms of % T/C was considered to be 125. The minimum effective dose reported in the following Table is that dose giving a % T/C of approximately 125. The two values given in each instance in the "average weight change" column are respectively the average weight change per mouse at the maximum effective dose and at the minimum effective dose.

Table I
Inhibition of P-388 Murine Leukemia

Compound No.	% T/C	Maximum Effect dose ¹	Minimum effective dose ¹	Average weight change ²
1 (BL-6787)	>333(294)	3.2(3.2)	0.2	-1.2, -0.3
3 (BL-6796)	>375(250)	6.4(3.2)	<0.2	-2.5, -0.9
4 (BL-6832)	172(194)	6.4(3.2)	0.8	-2.8, -0.9
5 (BL-6790)	>333(294)	12.8(3.2)	<0.2	-2.4, 0
6 (BL-6789)	183(294)	12.8(3.2)	0.4	-0.6, +0.8
7 (BL-6788)	200(294)	12.8(3.2)	0.2	-0.6, -0.2
8 (BL-6795)	188(250)	6.4(3.2)	0.8	-0.8, +0.1
9 (BMY-25036)	219(319)	3.2(3.2)	<0.2	-1.3, -0.6
11 (BMY-25066)	194(194)	3.2(1.6)	<0.2	-1.8, -0.7
12 (BMY-25067)	331(194)	12.8(1.6)	<0.2	-3.3, -1.1

¹ mg/kg of body weight

² grams per mouse, days 1-6, at maximum and minimum effective doses

Table II contains results of antitumor tests using the B16 melanoma grown in mice. BDF₁ mice were employed and inoculated subcutaneously with the tumor implant. A 60 day protocol was used. Groups of ten mice were used for each dosage amount tested and the mean survival

time for each group was determined. Control animals inoculated in the same way as the test animals and treated with the injection vehicle and no drug exhibited a mean survival time of 24.5 days. The survival time relative to that of the controls (% T/C) was used as a measure of effectiveness, and the maximal effective dose and minimal effective dose for each test compound was determined. The minimal effective dose was defined as that dose exhibiting a % T/C value of 125. For each dosage level, the test animals were treated with the test compound on days 1, 5, and 9 by the intravenous route.

Table II

10 Inhibition of B16 Melanoma

10

Compound No.	Maximum Effect % T/C	Effect Dose ¹	Minimum Effective Dose ¹	Average Wt. Change ²
15 1 (BL-6787)	122	3.0	3.0	- 2.7, - 2.7
6 (BL-6789)	163	3.0	<3.0	- 1.8, - 1.8
6 (BL-6789) ³	161	6.0	<3.0	- 1.4, - 1.3

15

¹ mg/kg of body weight20 ² grams per mouse, days 1-15, at maximum and minimum effective doses

20

³ treatment on days 5, 9, and 13

Compound No. 3 (BL-6796) was also evaluated for its effectiveness against the B16 melanoma grown in BDF₁ mice. In this experiment the animals were inoculated with the tumor by the intraperitoneal route and treatment with the test compound was also by intraperitoneal injection. Treatment occurred on days 1, 5, and 9 as before and mean survival times were determined. Again the minimal effective dose was considered to be that dose yielding a % T/C 125. At a dose of 1 milligram per kilogram of Compound No. 3, 6 of 10 animals survived the entire 60 day test period (% T/C 235) and exhibited an average weight change of + 0.1 grams on day 5. At a dose of 0.5 mg./kg. the mean survival time was 42.0 (% T/C 165) indicating that the minimal effective dose is less than 0.5 mg./kg. In the same test, mitomycin C exhibited % T/C 165 at a dose of 3 mg./kg. This was the maximal effective dose of mitomycin C in this experiment. It is thus evident that Compound No. 3 is several fold more potent against B16 melanoma in mice than mitomycin C.

25

30

The effects of Compounds 1 (BL-6787) and 3 (BL-6796) administered intravenously on the total and differential white blood cell (WBC) counts of mice were determined. Both compounds were found to be myelosuppressive, but apparently less so than mitomycin C. The results are given in Table III. The data for Compound 1 and mitomycin C were obtained in the same experiment, thus affording a direct comparison. Compound 1 was somewhat less myelosuppressive. The data for Compound 3, from a separate experiment, suggest still less myelosuppression, but a direct comparison with the other two compounds was not available.

35

40

Table III
White Blood Cell Counts

5 Compound No.	Dose (mg./kg., iv)		Cells per cc. ($\times 10^3$)			5
			Pretreatment	Day 4	Day 7	
1 (BL-6787)	6.4	t*	10 \pm 0.7	4 \pm 0.5	8 \pm 0.8	
		n	1.5 \pm 0.3	0.2 \pm 0.04	—	
		l	8.2 \pm 0.6	3.7 \pm 0.5	—	10
10 1 (BL-6787)	3.2	t	10 \pm 0.6	7 \pm 0.5	7 \pm 0.7	
		n	1.0 \pm 0.2	0.6 \pm 0.1	—	
		l	9.1 \pm 0.8	6.2 \pm 0.5	—	
3 (BL-6796)	8.8	t	10 \pm 0.6	4 \pm 0.7	11 \pm 0.7	
15		n	1.5 \pm 0.1	0.5 \pm 0.1	—	15
		l	7.8 \pm 0.6	3.7 \pm 0.5	—	
3 (BL-6796)	6.6	t	10 \pm 0.4	5 \pm 0.4	10 \pm 0.9	
		n	1.7 \pm 0.1	0.5 \pm 0.1	—	
		l	8.3 \pm 0.6	4.0 \pm 0.3	—	
20 mitomycin C	6.4	t	10.0 \pm 0.2	3 \pm 0.2	7 \pm 0.5	20
		n	1.0 \pm 0.2	0.1 \pm 0.02	—	
		l	9.0 \pm 0.3	2.5 \pm 0.2	—	
mitomycin C	3.2	t	9.0 \pm 0.7	4.0 \pm 0.7	9 \pm 0.5	
		n	0.7 \pm 0.1	0.2 \pm 0.02	—	
25		l	8.4 \pm 0.6	4.0 \pm 0.7	—	25

*t = total white blood cell count

n = neutrophils

l = lymphocytes

30

In view of the antitumor activity observed in experimental animal tumors, and the lack of undue myelosuppressive activity compared to mitomycin C, the invention includes use of the substances of the present invention for inhibiting mammalian tumors. For this purpose they are administered systematically to a mammal bearing a tumor in substantially non-toxic antitumor effective dose.

35

The compounds of the present invention are intended primarily for use by injection in much the same way and for some of the same purposes as mitomycin C. Somewhat larger or smaller doses may be employed depending upon the particular tumor sensitivity. They are readily distributed as dry pharmaceutical compositions containing diluents, buffers, stabilizers, solubilizers, and ingredients contributing to pharmaceutical elegance. These compositions are then constituted with an injectable liquid medium extemporaneously just prior to use. Suitable injectable liquids include water, isotonic saline, etc.

40

Description of Specific Embodiments

45

All temperatures in the following experimental procedures are expressed in degrees Centigrade. Proton magnetic resonance spectra (^1H NMR) were recorded on a Varian XL 100 or on a Jeol FX-90Q (90 MHz) spectrometer in pyridine d_5 unless otherwise stated. Infra red (IR) spectra were obtained with a Bechman Model 4240 spectrophotometer and the IR figures are ν_{max} in cm^{-1} . Thin layer chromatography (TLC) was carried out on 0.25 mm E. Merck precoated silica gel plates (60F-254) using ultra violet light and/or iodine vapors as visualizing agent. Flash chromatography (J. Org. Chem. 14, 2923, 1978) was performed using Silica Woelm (32–63 μm). Solvents were evaporated under reduced pressure and below 50°C.

50

Procedure 1

55

7-[2-(Benzyldithio)ethylamino]-9a-methoxymitosane (Compound 1)
Via Mitomycin A

To a solution of 200 mg. (0.28 mM) of S-benzyldithioethylamine, in 2 ml. of methanol containing 300 mg. of triethylamine there was added 99 mg. (28.3 mM) of mitomycin A in methanol (10 ml.) at 0°–4°C. The resulting solution was stirred at 20°C for 2.5 hr. The progress of the reaction was monitored by TLC using a 10:90 v/v methanol-chloroform solvent system. The reaction mixture was concentrated under reduced pressure to a dry solid residue, which on flash chromatography (35 g silica gel) using 7:93 v/v methanol-dichloromethane (800 ml.) as eluant afforded the title compound (87 mg., 59%) as a pure amorphous solid.

60

65 ^1H NMR (90 MHz, pyridine d_5 , δ): 2.08(s, 3H), 2.74(m, 3H), 3.16(d, 1H, J = 6Hz), 3.24(s,

3H), 3.40–4.20(m, 6H), 4.04(s, 2H), 4.56(d, 1H, J = 14Hz), 5.08(t, 1H, J = 12Hz), 5.40(dd, 1H, J = 6, 12Hz), 7.44(bs, 5H).

IR(BKr), ν_{\max} , cm^{-1} : 3440, 3350, 3290, 3060, 3020, 1720, 1635, 1560, 1325, 1060.

- 5 Anal. Calc'd for $\text{C}_{24}\text{H}_{28}\text{N}_4\text{O}_5\text{S}_2$: C, 55.80; H, 5.46; N, 10.84; S, 12.41
Found: C, 55.08; H, 5.31; N, 10.52; S, 12.10

5

Procedure 2

N-[2-(2-Aminoethyldithio)ethyl]acetamide (Compound 2)

10 a. Bunte Salt Method

10

A solution of 695 mg. of 2-aminoethanthiosulfuric acid (4.59 mM) in 7 ml. of methanol containing 318 mg. (7.95 mM) of sodium hydroxide was stirred for 10 minutes at room temperature and then cooled to 0°. *N*-Acetylcysteamine, 357 mg. (3.43 mM), was added to this solution and the solution was stirred for an additional 10 minutes. The resulting cloudy solution was diluted to about 60 ml. with methanol and this solution was then acidified by the careful addition of acetyl chloride (624 mg., 7.95 mM). The clear solution was evaporated to a waxy solid, which was directly used for conversion to Compound 3.

15

b. Sulfenylthiocarbonate Method

- 20 The method of S.J.Brois et al. (loc. cit.) was employed. Methyl-2-aminoethylsulfenylthiocarbonate hydrochloride in methanol solution was treated with acetylcysteamine at 0°C. The reaction, without triethylamine accelerator, was practically instantaneous.

20

Procedure 3

25 7-[2-(2-Acetylaminoethyldithio)ethylamino]-9a-methoxymitosane (Compound 3)

25

To a solution of 100 mg. (0.29 mM) of mitomycin A in 4 ml of methanol containing 200 mg. (198 mM) of triethylamine there was added at about 0° a solution of about 400 mg. of 2 in 2 ml. methanol. The precipitate which appeared was removed by filtration, and the clear filtrate was allowed to stand at room temperature for 4 hrs. The solution was evaporated to a dry residue and flash chromatographed on silica gel (10 g) using the gradient elution technique (4% to 8% methanol in methylene chloride). The desired product was the faster moving blue zone component which was isolated as an amorphous solid weighing 45 mg. (31.5%). An analytical sample was obtained by triturating the solid with 5% methylene chloride in hexane and drying the solid.

30

- 35 ^1H NMR (100 MHz, pyridine d_5 , δ): 2.06(s, 3H), 2.10(s, 3H), 2.76(bs, 1H), 2.80–3.20(m, 5H), 3.24(s, 3H), 3.60(dd, 1H, J = 12 and 2Hz), 3.70–4.10(m, 5H), 4.54(d, 1H, J = 12Hz), 5.04(t, 1H, J = 10Hz), 5.38(dd, 1H, J = 4 and 10Hz).

35

IR(KBr), ν_{\max} , cm^{-1} : 3420, 3350, 3290, 1720, 1635, 1656, 1330, 1060

Anal. Calc'd for $\text{C}_{21}\text{H}_{29}\text{N}_5\text{O}_6\text{S}_2$: C, 49.26; H, 5.67; N, 13.68; S, 12.51

- 40 Found: C, 49.33; H, 6.04; N, 13.20; S, 11.48

40

Procedure 4

7-[2-(Octyldithio)ethylamino]-9a-methoxymitosane (Compound 4)

Via 7-Substituted Amidino-9a-methoxymitosane

- 45 To a solution of 60 mg. (0.15 mM) 7-(dimethylaminomethylene)amino-9a-methoxymitosane in methanol (1 ml.) containing triethylamine (0.2 ml.) was added 139 mg. (0.54 mM) of 2-(octyldithio)ethylamine hydrochloride. The solution was allowed to stand at 0–4°C for 48 hrs. Thin layer chromatography using 10:90 v/v methanol-methylene chloride then revealed that the green-colored starting compound had been consumed, and a major blue zone (RF = 0.6) was visible. The solution was concentrated under reduced pressure to a solid residue, which was flash chromatographed on silica gel (12 g) using 20:1 v/v methylene chloride-methanol as the eluting solvent. The title compound was obtained as an amorphous solid (27 mg., 34%) whose ^1H NMR spectrum (100 MHz) is given in Table IV.

50

55 Procedures 5–22

55

Application of Various Dithio Amines

The amines identified in Table IV may be caused to react as described in either of Procedures 1, 3, or 4 to produce the products of Formulas I and II which are identified in the table.

Analytical and spectral data for some of the foregoing substances and some identified in Table IV are presented in Table V.

60

Table IV
Additional Products of Formulas I and II






Proc. No.	Formula*	R ⁷ Alk ₁ - or R ⁸ -	Alk ₂	Amine Reactant
5	I	H ₂ N(CH ₂) ₂ -	-(CH ₂) ₂ -	2-aminoethyl disulfide
6	II	phenyl	-(CH ₂) ₂ -	2-aminoethyl phenyl disulfide
7	II	n-butyl	-(CH ₂) ₂ -	2-aminoethyl n-butyl disulfide
8	I		-(CH ₂) ₂ -	N-[2-(2-aminoethylthio)ethyl]acetamide
9	(R is -COCH ₃) I	CH ₃ CONHCH ₂ CH ₂ - HOCH ₂ CH ₂	-(CH ₂) ₂ -	2-(2-aminoethylthio)ethanol
10	II		-(CH ₂) ₂ -	2-(2-aminoethylthio)pyridine
11	II		-(CH ₂) ₂ -	2-aminoethyl 4-methoxyphenyl disulfide
12	II		-(CH ₂) ₂ -	2-aminoethyl 4-nitrophenyl disulfide
13	I	C ₆ H ₅ CONH(CH ₂) ₂ -	-(CH ₂) ₂ -	N-[2-(2-aminoethylthio)ethyl]benzamide
14	I		-(CH ₂) ₂ -	N-[2-(2-aminoethylthio)ethyl]anisamide
15	I		-(CH ₂) ₂ -	N-[2-(2-aminoethylthio)ethyl]-4-nitrobenzamide
16	II	4-chloro-2-naphthyl	-(CH ₂) ₂ -	2-aminoethyl 4-chloro-2-naphthyl disulfide

Table IV (cont.)
Additional Products of Formulas I and II









17	II	$\text{CH}_3\text{O}_2\text{CCHCH}_2-$	$-(\text{CH}_2)_2-$	S-(2-aminoethylthio)cysteine, methyl ester
18	II	$\text{CH}_3\text{O}_2\text{CCHCH}_2-$ $\text{NH}_2\text{OCHCH}_2\text{C}_6\text{H}_5$	$-(\text{CH}_2)_2-$	S-(2-aminoethylthio)phenylalanyl cysteine, methyl ester
19	I	$\text{CH}_3\text{O}_2\text{CCHCH}_2-$ $\text{NHCOCHCH}_2\text{C}_6\text{H}_5$ NH_2	$-(\text{CH}_2)_2-$	6-mercaptoheptanoic acid, methyl ester
20	I		$-(\text{CH}_2)_6-$	6-[(cyclopropyl)methylthio]hexylamine
21	I		$-(\text{CH}_2)_2-$	2-aminoethyl 2-phenoxyethyl disulfide
22	II	2-pyrimidyl	$-(\text{CH}_2)_2-$	2-(2-aminoethylthio)pyrimidine
23	II		$-(\text{CH}_2)_2-$	1-[2-(2-aminoethylthio)ethyl]-2-pyrrolidone
24	II		$-(\text{CH}_2)_2-$	2-[2-(aminoethylthio)]benzimidazole
25	I	$\text{C}_2\text{H}_5\text{OC}-\text{NHCH}_2\text{CH}_2$ \parallel O	$-(\text{CH}_2)_2-$	2-aminoethyl 2-ethoxycarbonylaminoethyl disulfide
26	I	$\text{H}_2\text{NC}-\text{NH}(\text{CH}_2)_3-$ \parallel NH	$-(\text{CH}_2)_2-$	2-aminoethyl 3-guanidinopropyl disulfide

Table IV (cont.)
Additional Products of Formulas I and II

27	I	NO Cl(CH ₂) ₂ NCONH(CH ₂) ₂ -	-(CH ₂) ₂ -	H ₂ NCH ₂ CH ₂ -SS-CH ₂ ClCH ₂ CH ₂ NCONHCH ₂
28	II		-(CH ₂) ₂ -	NO 2-aminoethyl 2-nitrophenyl disulfide**
29	II		-(CH ₂) ₂ -	2-aminoethyl 2,4-dinitrophenyl disulfide**
30	II		-(CH ₂) ₂ -	2-aminoethyl 3-nitro-2-pyridyl disulfide
31	II		-(CH ₂) ₂ -	2-aminoethyl 5-nitro-2-pyridyl disulfide

* R of Formulas I and II is H unless indicated otherwise

* Prepared by reaction of 2-nitrophenylsulfenyl chloride or 2,4-dinitrophenylsulfenyl chloride with cysteamine hydrochloride in tetrahydrofuran at 0° according to the general method of Y. Nagao et al., Tetrahedron Letters No. 50, pp 5021-5024 (1978).

Table V

Compound	¹ H NMR Data (pyridine d ₅ , δ)	IR(KBr), ν _{max} (cm ⁻¹)	Elemental Analysis ^a
4 ^a	0.87(m, 3H), 1.23(bs, 10H), 1.70(m, 2H), 2.17(s, 3H), 2.76(t, 2H, 7Hz), 2.76(bs, 1H), 3.00(t, 2H, 7Hz), 3.14(d, 1H, 4Hz), 3.24(s, 3H), 3.60(dd, 1H, 3, 12Hz), 3.80-4.20(m, 3H), 4.54(d, 1H, 12Hz), 5.06(t, 1H, 10Hz), 5.40(dd, 1H, 4, 10Hz) 2.08(s, 3H), 2.72(d, 1H, 4Hz), 2.80-3.30(m, 5H), 3.20(s, 3H), 3.44(t, 2H), 3.56(dd, 1H, 2, 12Hz), 3.70-4.10(m, 3H), 4.48(d, 1H, 12Hz), 4.96(t, 1H, 10Hz), 5.33(dd, 1H, 10, 4Hz) 2.04(s, 3H), 2.76(bs, 1H), 3.00(m, 3H), 3.26(s, 3H), 3.62(d, 1H, 14Hz), 3.72-4.12(m, 3H), 4.52(d, 1H, 14Hz), 5.40(dd, 1H, 6, 12Hz) 0.60-1.80(m, 7H), 2.12(s, 3H), 2.72(m, 3H), 2.96(t, 2H, 8Hz), 3.12(d, 1H), 3.24(s, 3H), 3.60(dd, 1H, 2, 14Hz), 3.82(m, 3H), 4.50(d, 1H, 14Hz), 5.36(dd, 1H, 6, 12Hz) 2.05(s, 3H), 2.13(s, 3H), 2.15(s, 3H), 3.00(m, 4H), 3.20(s, 3H), 3.48(dd, 1H), 3.60(dd, 1H, 2, 14Hz), 3.77(d, 1H, 5Hz), 3.90(m, 4H), 4.06(dd, 1H, 4, 10Hz), 4.59(t, 1H, 10Hz), 4.74(d, 1H, 14Hz), 5.61(dd, 1H, 4, 10Hz), 7.28, 7.64	3440, 3350, 3290, 2950, 2920, 1720, 1635, 1560, 1320, 1060	T. C, 55.74; H, 7.11; N, 10.40; S, 11.90 F. C, 56.09; H, 6.86; N, 10.48; S, 12.15
5 ^a		3400, 3280, 2930, 1710, 1635, 1560, 1330, 1060	T. C, 45.13; H, 6.17; N, 13.85; S, 12.68 F. C, 44.82; H, 5.33; N, 12.96; S, 12.44
6 ^b		3440, 3350, 3290, 2960, 2930, 1720, 1635, 1560, 1330, 1060	T. C, 53.06; H, 5.42; N, 10.76; S, 12.32 F. C, 53.41; H, 4.73; N, 10.70; S, 12.52
7 ^b		3440, 3350, 3290, 2950, 2920, 1715, 1635, 1560, 1320, 1060	T. C, 52.26; H, 6.26; N, 11.61; S, 13.29 F. C, 52.78; H, 6.87; N, 9.89; S, 10.38
8 ^{a,c}		3420, 3350, 3290, 2830, 1710, 1650, 1635, 1560, 1320, 1060	T. C, 49.90; H, 5.64; N, 12.65; S, 11.58 F. C, 48.95; H, 5.37; N, 12.22; S, 12.54

Table V (cont.)

Compound	¹ H NMR Data (pyridine d ₆ , δ)	IR(KBr), ν _{max} (cm ⁻¹)	Elemental Analysis ^a
9 ^b	2.12(s, 3H), 2.76(bs, 1H), 3.12(m, 5H), 3.24(s, 3H), 3.60(dd, 1H, 2, 14Hz), 4.00(m, 6H), 4.52(d, 1H, 14Hz), 5.04(t, 1H, 12Hz), 5.40(dd, 1H, 6, 12Hz)	3430, 3360, 3280, 2920, 1710, 1630, 1550, 1325, 1055	T. C, 48.50; H, 5.57; N, 11.91; S, 13.63 F. C, 48.73; H, 5.82; N, 11.06; S, 13.67
10 ^b	2.04(s, 3H), 2.74(bs, 1H), 3.08(m, 3H), 3.24(s, 3H), 3.60(dd, 1H, 2, 14Hz), 3.92(m, 3H), 4.52(d, 1H, 14Hz), 5.02(t, 1H, 12Hz), 5.36(dd, 1H, 6, 12Hz), 7.16, 7.56, 8.72	3430, 3350, 3280, 2930, 1720, 1630, 1555, 1325, 1060,	T. C, 52.47; H, 5.00; N, 13.91; S, 12.73 F. C, 46.37; H, 4.42; N, 11.88; S, 11.26
11 ^b	2.04(s, 3H), 2.72(bs, 1H), 3.04(m, 3H), 3.22(s, 3H), 3.58(dd, 1H, 2, 14Hz), 3.68(s, 3H), 3.92(m, 3H), 4.52(d, 1H, 14Hz), 5.04(t, 1H, 12Hz), 5.38(dd, 1H, 6, 12Hz), 7.34 (AB quartet, 4H)	3440, 3360, 3300, 2940, 1720, 1635, 1555, 1335, 1060	T. C, 54.12; H, 5.30; N, 10.52; S, 12.04 F. C, 53.30; H, 5.32; N, 10.61; S, 12.13
12 ^b	2.04(s, 3H), 2.74(bs, 1H), 3.08(m, 3H), 3.24(s, 3H), 3.60(dd, 1H, 2, 14Hz), 3.96(m, 3H), 4.52(d, 1H, 14Hz), 5.04(t, 1H, 12Hz), 5.40(dd, 1H, 6, 12Hz), 8.04 (AB quartet, 4H)	3460, 3360, 3300, 2940, 1720, 1635, 1555, 1340, 1060	T. C, 50.45; H, 4.60; N, 12.79; S, 11.71 F. C, 49.25; H, 4.55; N, 12.78; S, 11.69
28 ^a	2.00(s, 3H), 2.17(m, 1H), 2.77(bs, 1H), 3.03(t, 2H), 3.17(bs, 1H), 3.23(s, 3H), 3.60(d, 1H, 12.8 Hz), 3.87(dt, 2H), 4.00(dd, 1H, 4.2 Hz, 11.1 Hz), 4.51(d, 1H, 12.8 Hz), 5.10(t, 1H), 5.40(dd, 1H, 4.2 Hz, 10.3 Hz), 7.32(m, 2H), 7.71(t, 1H), 8.28(dd, 1H)	3460, 3350, 3285, 2940, 1720, 1635, 1560, 1510, 1450, 1335, 1060	T. C, 48.33; H, 4.47; N, 12.04 F. C, 48.37; H, 4.56; N, 12.02 (corrected for 0.4M % CH ₂ Cl ₂)
29 ^a	2.03(s, 3H), 2.15(bs, 1H), 2.75(bs, 1H), 3.14(t, 2H), 3.24(s, 3H), 3.24(bs, 1H), 3.60(d, 1H), 3.94(dt, 2H), 4.00(dd, 1H, 4.1 Hz, 11.2 Hz), 4.50(d, 1H, 12.7 Hz), 5.36(dd, 1H, 4.1 Hz, 10.3 Hz), 7.32(m, 1H), 8.53(m, 1H)	3460, 3360, 3290, 3105, 2940, 1715, 1635, 1555, 1340, 1060	T. C, 44.51; H, 3.97; N, 13.25 F. C, 44.56; H, 3.93; N, 12.85 (corrected for 0.5M % CH ₂ Cl ₂)

Table V (cont.)

Compound	¹ H NMR Data (pyridine d ₅ , δ)	IR(KBr), ν _{max} (cm ⁻¹)	Elemental Analysis ^a
30 ^b	2.08(s, 3H), 2.18(m, 1H), 2.77(bs, 1H), 3.17 (m, 3H), 3.24(s, 3H), 3.61(d, 1H, 12.4 Hz), 3.87(dt, 2H), 4.03(dd, 1H, 4.1 Hz, 11.1 Hz), 4.55(d, 1H, 12.7 Hz), 5.12(t, 1H), 5.43(dd, 1H, 4.2 Hz, 10.3 Hz), 7.33(dd, 1H, 4.8 Hz, 8.4 Hz), 7.85(t, 1H), 8.50(d, 1H, 8.2 Hz), 9.13(d, 1H, 4.8 Hz)	3460, 3350, 3280 3065, 2930, 1720, 1630, 1550, 1335 1060	T: C, 45.72; H, 4.26; N, 14.22 F: C, 45.72; H, 4.39; N, 14.31 (corrected for 0.5M % CH ₂ Cl ₂)
31 ^b	2.04(s, 3H), 2.04(bs, 1H), 2.76(bs, 1H), 3.12(m, 3H), 3.22(s, 3H), 3.56(d, 1H, 14 Hz), 3.90(m, 3H), 4.48(d, 1H, 14 Hz), 5.00(t, 1H, 12.0 Hz), 5.36(dd, 1H, 4.3 Hz, 12.0 Hz), 7.92(d, 1H, 10.0 Hz), 8.52 (dd, 1H, 4 Hz, 10 Hz), 9.52(d, 1H, 4Hz)	3465, 3345, 3280, 3060, 2930, 1720 1630, 1585, 1555, 1340, 1055	T: C, 46.18; H, 4.29; N, 14.43 F: C, 46.19; H, 4.32; N, 13.91 (corrected for 0.4M % CH ₂ Cl ₂)

a. 100 MHz NMR Spectrum

b. 90 MHz NMR Spectrum

c. Prepared by acylation of Compound 5 with acetic anhydride and pyridine

d. T = Theory, F = Found

e. 360 MHz NMR Spectrum

Table I Addendum
Inhibition of P-388 Murine Leukemia³

Compound No.	Maximum % T/C	Effect. Dose ¹	Minimum Effective Dose ¹	Average weight change ²
28 (BMY-25828)	220(270)	6.4(4.8)	<0.4	- 1.1, + 3.2
29 (BMY-25829)	170(270)	3.2(4.8)	<0.2	+ 2.6, + 2.7
30 (BMY-25827)	200(270)	12.8(4.8)	<0.4	- 3.2, + 1.0
31 (BMY-25830)	170(270)	3.2(4.8)	<0.2	+ 1.3, + 0.5

¹ mg/kg body weight


² grams per mouse, days 1-7, at maximum and minimum effective dose

³ male CDF₁ mice

It will of course be understood that the present invention has been described above purely by way of example, and modifications of detail can be made within the scope and spirit of the invention.

CLAIMS

1. A compound having the formula



wherein:


Alk₂ is a straight or branched chain alkylene group having 2 to 6 carbon atoms optionally bearing an R⁷ substituent wherein the sulfur and nitrogen atoms connected thereto and any optional R⁷ substituent connected thereto through oxygen, sulfur or nitrogen are attached to different carbon atoms of Alk₂.

R is hydrogen, lower alkyl, lower alkanoyl, benzoyl, or substituted benzoyl wherein said substituent is lower alkyl, lower alkoxy, halo, amino, or nitro.

R⁷ is selected from the group consisting of hydroxy, halo, amino, alkylamino or dialkylamino having 1 to 12 atoms, alkanoylamino, benzoylamino or A-substituted benzoylamino, naphthoylamino or A-substituted naphthoylamino, cycloalkyl or A-substituted cycloalkyl each having 3 to 8 ring members, cycloalkenyl or A-substituted cycloalkenyl each having 5 to 8 ring members, phenyl or A-substituted phenyl, naphthyl or A-substituted naphthyl, a heterocyclic group selected from the group consisting of heteroaromatic and heteroalicyclic groups having from 1 to 2 rings; from 3 to 8 ring members in each ring, and from 1 to 4 hetero atoms selected from oxygen, nitrogen, and sulfur, alkoxy or alkythio each having 1 to 6 carbon atoms, carboxy, alkoxycarbonyl having 1 to 7 carbon atoms, phenoxycarbonyl or A-substituted phenoxycarbonyl, phenoxy or A-substituted phenoxy, naphthoxy or A-substituted naphthoxy, alkoxycarbonylamino having 2 to 6 carbon atoms, guanidino, ureido (-NHCONH₂), N-alkylureylene (-NHCONHalkyl) having 2 to 7 carbon atoms, N³-haloalkylureylene having 3 to 7 carbon atoms, N³-haloalkyl-N³-nitrosoureylene having 3 to 7 carbon atoms, and dialkylaminocarbonyl having 3 to 13 carbon atoms, wherein said A substituent is selected from the group consisting of one or two lower alkyl, lower alkanoyl, lower alkoxy, halo, amino, hydroxy or nitro groups, and

R⁹ is an organic group.


2. A compound selected from the group having Formula I or Formula II:



5

10

10



15

20 wherein:

20

Alk₁ is a straight or branched chain alkylene group having 1 to 6 carbon atoms when R⁷ is joined thereto through a carbon atom thereof, and 2 to 6 carbon atoms when R⁷ is joined thereto through a sulfur, oxygen, or nitrogen atom thereof, and R⁷ and -SS- are in that instance joined to different carbon atoms

25 Alk₂ is a straight or branched chain alkylene group having 2 to 6 carbon atoms optionally bearing an R⁷ substituent wherein the sulfur and nitrogen atoms connected thereto and any optional R⁷ substituent connected thereto through oxygen sulfur or nitrogen are attached to different carbon atoms of Alk₂.

25

Alk₁ and Alk₂ may contain a double bond,

30 R is hydrogen, lower alkyl, lower alkanoyl, benzoyl, or substituted benzoyl wherein said substituent is lower alkyl, lower alkoxy, halo, amino, or nitro,

30

R⁷ is selected from the group consisting of hydroxy, halo, amino, alkylamino or dialkylamino having 1 to 12 atoms, alkanoylamino, benzoylamino or A-substituted benzoylamino, naphthoylamino or A-substituted naphthoylamino, cycloalkyl or A-substituted cycloalkyl each having 3 to 8 ring members, cycloalkenyl or A-substituted cycloalkenyl each having 5 to 8 ring members, phenyl or A-substituted phenyl, naphthyl or A-substituted naphthyl, a heterocyclic group selected from the group consisting of heteroaromatic and heteroalicyclic groups having from 1 to 2 rings, from 3 to 8 ring members in each ring, and from 1 to 4 hetero atoms selected from oxygen, nitrogen, and sulfur, alkoxy or alkylthio each having 1 to 6 carbon atoms, carboxy, alkoxycarbonyl having 1 to 7 carbon atoms, phenoxycarbonyl or A-substituted phenoxycarbonyl, phenoxy or A-substituted phenoxy, naphthoxy or A-substituted naphthoxy, alkoxycarbonylamino having 2 to 6 carbon atoms, guanidino, ureido (-NHCONH₂), N-alkylureylene (-NHCONHalkyl) having 2 to 7 carbon atoms, N³-haloalkylureylene having 3 to 7 carbon atoms, N³-haloalkyl-N³-nitrosoureylene having 3 to 7 carbon atoms, and dialkylaminocarbonyl having 3 to 13 carbon atoms, wherein said A substituent is selected from the group consisting of one or two lower alkyl, lower alkanoyl, lower alkoxy, halo, amino, hydroxy, or nitro groups, and

35

40

45

R⁸ is selected from the group consisting of alkyl having 1 to 12 carbon atoms, alkenyl or alkynyl each having 3 to 12 carbon atoms, cycloalkyl having 3 to 8 ring members, A-substituted cycloalkyl having 3 to 8 ring members, cycloalkenyl having 5 to 8 ring members, phenyl, A-substituted phenyl, naphthyl, A-substituted naphthyl, a heterocyclic group selected from the group consisting of heteroaromatic and heteroalicyclic groups having from 1 to 2 rings, from 3 to 8 ring members in each ring, and from 1 to 4 hetero atoms selected from oxygen, nitrogen, and sulfur, wherein said A substituent is selected from the group consisting of one or two lower alkyl, lower alkanoyl, lower alkoxy, halo, amino, hydroxy or nitro groups, and R⁸ and the adjacent sulfur atom together constitute S-cysteinyl wherein said S-cysteinyl group may be esterified, salified, or joined within a peptide bond.

50

55

3. The compound of Claim 2 having Formula I wherein Alk₂ is ethylene and R is hydrogen.

60 4. The compound of Claim 3 wherein Alk₁ is ethylene.

60

5. The compound of Claim 2 known by the chemical name 7-[2-(2-aminoethyldithio)ethylamino]-9a-methoxymitosane.

6. The compound of Claim 2 having the chemical name 7-[2-(2-acetylaminoethyldithio)ethylamino]-9a-methoxymitosane.

65 7. The compound of Claim 2 having Formula II wherein Alk₂ is ethylene and R is hydrogen.

65

8. The compound of Claim 7 wherein R^8 is alkyl.

9. The compound of Claim 2 having the chemical name 7-[2-(octyldithio)ethylamino]-9a-methoxymitosane.

10. The compound of Claim 2 having the chemical name 7-[2-(n-butyldithio)ethylamino]-9a-methoxymitosane. 5

11. The compound of Claim 2 7-[2-(benzyldithio)ethylamino]-9a-methoxymitosane.

12. The method of inhibiting growth of a mammalian tumor which comprises systemic administration to a mammal bearing a tumor a substantially non-toxic antitumor effective dose of a compound of Claim 2.

10 13. The process for the preparation of a compound of Claim 2 which comprises contacting from 1 to 4 molecular proportions of an amine having Formulas III or IV 10




15 III

IV

15

with 1 molecular proportion of a mitosane of Formula V

20



V

20


25

25

wherein R, R^7 , R^8 , alk_1 and alk_2 are the same as defined in Claim 2 and Y is lower alkoxy of 1 to 6 carbon atoms or a group having Formula VI

30

30



35

VI

35

wherein

R^5 is hydrogen, lower alkyl, phenyl, lower alkylphenyl, lower alkoxyphenyl, halophenyl, aminophenyl or nitrophenyl,

40 R^3 and R^4 are independently lower alkyl, or together with the nitrogen atom to which they are attached constitute pyrrolidine, 2-, or 3-lower alkylpyrrolidine, piperidine, 2,3-, or 4-lower alkylpiperidine, 2,6-dilower alkylpiperidine, piperazine 4-substituted piperazine (wherein said 4-substituent is alkyl, or carbalkoxy each having 1 to 8 carbon atoms, phenyl, methylphe- 45 nyl, methoxyphenyl, halophenyl, nitrophenyl, or benzyl), azepine 2-,3-,4-, or 5-lower alkylazepine, morpholine, thiomorpholine, thiomorpholine-1-oxide, or thiomorpholine-1, 1-dioxide,

wherein

each of the aforesaid lower alkyl, lower alkanoyl and lower alkoxy groups contains 1 to 6 carbon atoms

50 under reaction conditions in a reaction inert organic liquid at a temperature of from about -15 to $+50^\circ\text{C}$ for a period of sufficient duration to result in formation of an appreciable amount of the product of Formula I or Formula II. 50

14. The compound of Claim 2 having the chemical name 7-[2-(phenyldithio)ethylamino]-9a-methoxymitosane.

55 15. The compound of Claim 2 having the chemical name 7-[2-(2-hydroxyethylthio)ethylamino]-9a-methoxymitosane. 55

16. The compound of Claim 2 having the chemical name 7-[2-(2-pyridyldithio)ethylamino]-9a-methoxymitosane.

17. The compound of Claim 2 having the chemical name 7-[2-(4-methoxyphenyldithio)ethylamino]-9a-methoxymitosane. 60

18. The compound of Claim 2 having the chemical name 7-[2-(4-nitrophenyldithio)ethylamino]-9a-methoxymitosane.

19. The compound of Claim 2 having the chemical name 7-[2-(2-nitrophenyldithio)ethylamino]-9a-methoxymitosane.

65 20. The compound of Claim 2 having the chemical name 7-[2-(2,4-dinitrophenyldithio)ethylamino]-9a-methoxymitosane. 65

lamino]-9a-methoxymitosane.

21. The compound of Claim 2 having the chemical name 7-[2-(3-nitro-2-pyridyldithio)ethy-lamino]-9a-methoxymitosane.

22. The compound of Claim 2 having the chemical name 7-[2-(5-nitro-2-pyridyldithio)ethy-lamino]-9a-methoxymitosane.

5 10

23. A process as claimed in claim 13, substantially as indicated in respect of any of the foregoing exemplifying Procedures.

24. A pyrroloindole derivative prepared by a process as claimed in claim 13 or 23.

10 1-11, 14-22 and 24, and a pharmaceutically acceptable carrier or vehicle therefor. 10

Printed in the United Kingdom for Her Majesty's Stationery Office, Dd 8818935, 1984, 4235.
Published at The Patent Office, 25 Southampton Buildings, London, WC2A 1AY, from which copies may be obtained.